Journal
BLOOD
Volume 125, Issue 12, Pages 1847-1848Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2015-02-625251
Keywords
-
Categories
Ask authors/readers for more resources
In this issue of Blood, Duvic et al demonstrate that mogamulizumab, a humanized monoclonal antibody targeting the chemokine receptor CCR4, is well tolerated and has significant clinical activity (overall response rate 36.8%, median duration of response 10.4 months) in heavily pretreated patients with mycosis fungoides (MF) and Sezary syndrome (SS).1
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available